Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer

Clinical Lung Cancer
Leonard T OngAbraham J Wu

Abstract

Whether (18)F-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) metrics predict outcome in limited-stage (LS) small-cell lung cancer (SCLC) has not been well established; most previous reports have only analyzed maximal standardized uptake values (SUVmax). We investigated multiple pretreatment PET metrics, including SUVmax, mean SUV (SUVmean), total lesion glycolysis, and metabolic tumor volume (MTV) in LS-SCLC patients undergoing chemoradiotherapy (CRT) and correlated them with survival and disease control outcomes. All patients received platinum-based chemotherapy and a median radiation dose of 45 Gy. Kaplan-Meier and competing-risks analyses were performed to assess the prognostic value of PET metrics with respect to overall survival (OS), distant failure (DF), disease-free survival (DFS), and locoregional failure (LRF). Univariate and multivariate analyses were performed to account for the effect of other clinical factors on outcomes. A total of 120 patients with LS-SCLC had analyzable pre-CRT PET/CTs. The median follow up was 34 months. Median OS was 26.9 months. OS was 53.2% at 2 years and 33.1% at 5 years. SUVmax, SUVmean, MTV, and total lesion glycolysis of the primary tumor were not significan...Continue Reading

References

Aug 16, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Ronald BoellaardJan Pruim
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Feb 5, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Dongyuan ZhuJinming Yu
Apr 15, 2011·International Journal of Radiation Oncology, Biology, Physics·Shervin M ShirvaniJoe Y Chang
Oct 15, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C van der LeestJ G J V Aerts
Jan 25, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Jong-Ryool OhHee-Seung Bom
Mar 20, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Giovanni Luca Ceresoli
Sep 4, 2012·International Journal of Oncology·Daniel E GomezDaniel F Alonso

❮ Previous
Next ❯

Citations

Dec 28, 2019·The Journal of International Medical Research·Eun Kyoung ChoiJin Kyoung Oh
Feb 3, 2018·Nuclear Medicine and Molecular Imaging·Hyoungwoo KimSung Hoon Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Carcinoma, Bronchogenic

Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.